Patents Issued in April 16, 2019
  • Delivery devices containing encapsulated and/or practice-bound active pharmaceutical ingredients
    Patent number: 10258571
    Abstract: Delivery devices of a degradable or nondegradable biocompatible matrix with one or more encapsulated active pharmaceutical ingredients or one or more particle-bound active pharmaceutical ingredients dispersed in the matrix are provided. Also provided are methods for delivering an active pharmaceutical ingredient to a subject with these delivery devices. Modified vaginal rings are also provided as well as surface coatings for delivery devices which minimize bio-interaction of the coated delivery devices.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: April 16, 2019
    Assignee: PARTICLE SCIENCES, INC.
    Inventors: David Fairhurst, Garry Thomas Gwozdz, Mark Mitchnick, Abhijit Gokhale, Andrew Loxley
  • Pharmaceutical compositions of goserelin sustained release microspheres
    Patent number: 10258572
    Abstract: A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly (lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: April 16, 2019
    Assignee: Shandong Luye Pharmaceutical Co., Ltd.
    Inventors: Wei Sun, Xuemei Zhang, Tao Wang, Guangyi Leng, Kaoxiang Sun, Youxin Li, Wanhui Liu
  • Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditions
    Patent number: 10258573
    Abstract: A method of preparing an inhalable insulin suitable for pulmonary delivery includes: dissolving an insulin raw material in an acidic solution to form a dissolved insulin solution; titrating the dissolved insulin solution with a buffer solution to form a suspension comprising micronized insulin particles; and stabilizing the micronized insulin particles.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 16, 2019
    Assignee: Amphastar Pharmaceuticals, Inc.
    Inventors: Jeffrey Ding, Aili Bo, Mary Ziping Luo, Jack Yongfeng Zhang
  • Method of preparing itraconazole preparation
    Patent number: 10258574
    Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: April 16, 2019
    Assignees: CHANGZHOU PHARMACEUTICAL FACTORY CO., LTD., CRYSTEC LTD.
    Inventors: Xuezhi Yin, Linda Sharon Daintree, Sheng Ding, Daniel Mark Ledger, Bing Wang, Wenwen Zhao, Wei Wu, Jiansheng Han
  • Oral drug dosage forms having desired drug release profiles and uses thereof
    Patent number: 10258575
    Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: April 16, 2019
    Assignee: Triastek, Inc.
    Inventor: Xiaoling Li
  • Particulate comprising a calcium-containing compound and a sugar alcohol
    Patent number: 10258576
    Abstract: The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: April 16, 2019
    Assignee: Takeda AS
    Inventors: Jacob Mathiesen, Carsten Martini Nielsen, Peder Mohr Olsen, Poul Egon Bertelsen
  • Multilayer solid pharmaceutical dosage forms
    Patent number: 10258577
    Abstract: Disclosed is a multilayer solid pharmaceutical dosage form, wherein a core containing an active ingredient is coated with a first sustained-release coating layer, a drug layer containing the active ingredient is applied onto the first layer, and a second sustained-release coating layer is applied onto the drug layer.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: April 16, 2019
    Assignee: NOVAST LABORATORIES LTD
    Inventors: Yisheng Chen, Guohua Zhang, Manman Liu
  • Crosslinked particles
    Patent number: 10258578
    Abstract: Disclosed are crosslinked particles (e.g., microparticles) that are capable of storing and releasing drugs. The particles can be macroparticles, microparticles, or nanoparticles and can be composed of polyester backbones. The particles can be loaded with a drug. The particles can degrade in vivo to release the drug. The particles can be prepared by crosslinking functionalized polyester backbones and loaded with a given drug. The particles of the present disclosure can be injected with a syringe. In some embodiments, the particles of the present disclosure are administered in connection with a surgery and release the drug after the site of the surgery for a period of 1-6 months.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: April 16, 2019
    Assignee: PENDANT BIOSCIENCES, INC.
    Inventors: Frantz Le Dévédec, Christine Jane Allen, David M. Stevens, Dean James Rager-Aguiar, Timothy Tordella Ruckh, Carl Eric Elmquist
  • Process for the preparation of polysaccharide nanoparticles
    Patent number: 10258579
    Abstract: A process for the preparation of nanoparticles from polysaccharides and derivatives thereof, by their specific partial oxidation to produce aldehyde groups and attachment of compounds with amino or other group with the R—NH2 bond which react with aldehyde groups, and a nanoparticle produced by such process.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: April 16, 2019
    Assignee: NANOVELOS SP. Z O.O.
    Inventors: Tomasz Ciach, Iga Wasiak
  • Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
    Patent number: 10258580
    Abstract: The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: April 16, 2019
    Assignee: GW Pharma Limited
    Inventors: Teresa Iuvone, Vincenzo Di Marzo, Geoffrey Guy, Stephen Wright, Colin Stott
  • Organosulfur compounds for the prevention and treatment of neurodegenerative diseases
    Patent number: 10258581
    Abstract: Divalent salts of S-allylmercapto-N-acetylcysteine and related compositions are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compositions include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 16, 2019
    Inventor: David Michael Ott
  • Nicotinic receptor non-competitive antagonists
    Patent number: 10258582
    Abstract: The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: April 16, 2019
    Assignee: Catalyst BioSciences, Inc.
    Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Ronald Joseph Heemstra, Jason Speake, Daniel Yohannes, Matt S. Melvin, Yunde Xiao
  • Extended release liquid compositions of guanfacine
    Patent number: 10258583
    Abstract: The present invention relates to extended release liquid compositions of guanfacine. The extended release liquid compositions of the present invention are bioequivalent to marketed extended release tablet compositions of guanfacine. Said extended release liquid compositions provide substantially similar in-vitro dissolution release profile upon storage for at least seven days. Further, the extended release liquid compositions are stable. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: April 16, 2019
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Romi Barat Singh, Kalaiselvan Ramaraju, Balaram Mondal, Ashish Kumar, Suchitra Kaushik
  • Pregabalin sustained-release preparation
    Patent number: 10258584
    Abstract: Disclosed is a pregabalin sustained-release preparation, wherein the sustained-release tablet contains a pharmaceutically active ingredient containing pregabalin or a salt or hydrate thereof, a gel framework material containing alginic acid, and a swellable material containing polyoxyethylene.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: April 16, 2019
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Jiajia Xu, Hao Chen
  • DOPA decarboxylase inhibitor compositions
    Patent number: 10258585
    Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 16, 2019
    Assignee: NeuroDerm, Ltd.
    Inventor: Oron Yacoby-Zeevi
  • Methods and compositions for the treatment of diverticulosis
    Patent number: 10258586
    Abstract: The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Emmanus Medical, Inc.
    Inventor: Yutaka Niihara
  • Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
    Patent number: 10258587
    Abstract: The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent or treat the gastrointestinal condition in the subject. The present invention is also directed to methods of promoting gastrointestinal health in a subject and propagation of probiotic organisms. Also disclosed is a formulation which includes one or more branched chain fatty acid and an aqueous phase emulsified with the one or more branched chain fatty acids, where the formulation includes over 25 wt % of the one or more branched chain fatty acid.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: April 16, 2019
    Assignee: Cornell University
    Inventors: James Thomas Brenna, Rinat Ran-Ressler
  • Controlled release fatty acid compositions for use in body reconstruction and body-shaping
    Patent number: 10258588
    Abstract: The present invention is directed to compositions comprising physiologically acceptable, metabolic lipids, and physiologically acceptable, preferably biodegradable controlled release (CR) compounds, wherein the lipids are cell-free and the CR compounds release the metabolic lipids over a delayed time period under physiological conditions. In addition, the present invention relates to the use of such a composition for producing a cosmetic or therapeutic composition, preferably for fat tissue expansion or fat tissue repair. Also, the invention pertains to a method for the therapeutic or cosmetic treatment of a mammal comprising the administration of the composition of the invention and preferably injecting the composition while withdrawing the injection needle until the tissue area of interest is treated.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: April 16, 2019
    Assignee: PB&B SA
    Inventors: Anthony Youri Aho, Raghunathan Sandeep
  • Nitrated-fatty acids modulation of type II diabetes
    Patent number: 10258589
    Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 16, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Enteral feeding device and related methods of use
    Patent number: 10258590
    Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: April 16, 2019
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
  • Compositions and methods of use of phorbol esters
    Patent number: 10258592
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: April 16, 2019
    Assignee: BIOSUCCESS BIOTECH CO. LTD.
    Inventors: Hung-Fong Chen, Zheng Tao Han
  • Semiochemical compositions to reduce social conflicts with cats
    Patent number: 10258593
    Abstract: A semiochemical composition including methyl laurate, methyl myristate, methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities is described. Methods to reduce social conflicts in multi-cat households or in catteries or kennels boarding cats are also disclosed, as well as methods for inducing social facilitation in cats.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 16, 2019
    Assignee: INSTITUT DE RECHERCHE EN SEMIOCHIMIE ET ETHOLOGIE APPLIQUEE
    Inventor: Patrick Pageat
  • Cat appeasing pheromone
    Patent number: 10258594
    Abstract: Disclosed is a semiochemical composition including methyl palmitate, methyl linoleate, methyl oleate methyl stearate, methyl laurate, methyl myristate, salts thereof, derivatives thereof, isomers thereof and/or structural analogues thereof that have an appeasing effect in cats and/or also effects social facilitation in cats, and an acceptable vehicle. Solutions such as spot-on formulations of long duration are also encompassed. Methods to effect appeasing in a cat and/or social facilitation in cats are also disclosed.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 16, 2019
    Assignee: INSTITUT DE RECHERCHE EN SEMIOCHIMIE ET ETHOLOGIE APPLIQUEE
    Inventor: Patrick Pageat
  • Pharmaceutical formulation for histone deacetylase inhibitors
    Patent number: 10258595
    Abstract: A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 16, 2019
    Assignee: Medivir AB
    Inventors: Todd W. Chappell, Keith A. Johnson
  • Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
    Patent number: 10258596
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: April 16, 2019
    Assignee: GTx, Inc.
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
  • Method for treating a glycoprotein-related disease
    Patent number: 10258597
    Abstract: A method for treating a glycoprotein-related disease is disclosed, which comprises: administering a first effective amount of phenol red and a second effective amount of an organic arsenic compound to a subject in need thereof.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: April 16, 2019
    Inventor: Ming-Chang Lu
  • Compounds for use in the prevention or treatment of cancer
    Patent number: 10258598
    Abstract: The invention relates to the field of prevention and treatment of cancer, in particular suppression of tumor manifestation. The invention also relates to compounds for use in this field. A novel tumor manifestation suppression (TMS) regulation in a mammalian brain is recognized. The invention relates to compounds, pharmaceutical preparations, in particular medicaments for use in the prevention and treatment of cancer, in particular suppression of tumor manifestation based on said TMS regulation as well as methods for the same.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: April 16, 2019
    Assignees: Semmelweis University, Fujimoto Co. Ltd.
    Inventors: József Knoll, Ildikó Miklya, Péter Ferdinandy, Dezso Schuler, Zsuzsanna Schaff, Sándor Eckhardt
  • Compounds for use in the prevention or treatment of cancer
    Patent number: 10258599
    Abstract: The invention relates to the field of prevention and treatment of cancer, in particular suppression of tumor manifestation. The invention also relates to compounds for use in this field. A novel tumor manifestation suppression (TMS) regulation in a mammalian brain is recognized. The invention relates to compounds, pharmaceutical preparations, in particular medicaments for use in the prevention and treatment of cancer, in particular suppression of tumor manifestation based on said TMS regulation as well as methods for the same.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: April 16, 2019
    Assignees: Semmelweis University, Fujimoto Co. Ltd.
    Inventors: József Knoll, Ildikó Miklya, Péter Ferdinandy, Dezso Schuler, Zsuzsanna Schaff, Sándor Eckhardt
  • Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
    Patent number: 10258600
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: April 16, 2019
    Assignees: Trustees of Boston University, Boston Medical Center, Northeastern University
    Inventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
  • Vaporizable cannabinoid compositions
    Patent number: 10258601
    Abstract: A composition for producing a pharmacological effect is provided, which includes a bio-active ingredient and a carrier liquid solution. The bio-active ingredient can be a cannabinoid, cannabinomimetic, or combination thereof capable of inducing a pharmacological effect. The cannabinomimetic can be or can include one or more isoprenoids. The carrier liquid composition can include ethanol, at least one lecithin, at least one fatty alcohol, a liposome, and an active compound that includes glycerin or glycerol. The bio-active ingredient is receivable by a cannabinoid receptor and/or an acetylcholine receptor, which causes the production of the pharmacological effect. The composition may also include flavoring agents and aromatherapy agents. The composition is deliverable to a user via vaporization. A method is provided for creating a pharmacological effect using the composition.
    Type: Grant
    Filed: December 23, 2017
    Date of Patent: April 16, 2019
    Inventor: Stephen C. Perry
  • Macrocyclic ghrelin receptor modulators and methods of using the same
    Patent number: 10258602
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 16, 2019
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
  • Therapeutic compounds and uses thereof
    Patent number: 10258603
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 16, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
  • Lasofoxifene treatment of breast cancer
    Patent number: 10258604
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 16, 2019
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Use of indole compounds for fat reduction and skin and soft tissue tightening
    Patent number: 10258605
    Abstract: The present invention relates to indole compounds and compositions and uses thereof, including uses of the indole compounds and compositions for the reduction or removal of localized fat deposits and/or tightening of skin and soft tissue laxity in subjects. The indole compounds can be employed, for example, in the cosmetic sector or for producing pharmaceutical products.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: April 16, 2019
    Assignee: Alevere Medical Corporation
    Inventors: Diane Duncan, Tim Kamerzell, Mark Palmer
  • Endothelin single nucleotide polymorphisms and methods of predicting ?-adrenergic receptor targeting agent efficacy
    Patent number: 10258606
    Abstract: The present invention concerns the use of methods for evaluating ?-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a ?-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a ?-blocker. Accordingly, methods of treatment are also described.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: April 16, 2019
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Matthew R. G. Taylor, Luisa Mestroni
  • Method of increasing intratumoral pHe and reducing acid-mediated invasion
    Patent number: 10258607
    Abstract: A method of treating cancer or inhibiting metastasis in a subject by increasing intratumoral extracellular pH is presented. The method includes administering to the subject a therapeutically effective amount of a buffer having a pKa greater than 6.1. In an advantageous embodiment the pKa of the buffer is about 7.0. Examples of buffers for increasing extracellular pH include NaHCO3, 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), cholamine chloride, N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES) and 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES). The method can further include the step of pretreating with one or more chemotherapeutic agents.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: April 16, 2019
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Robert J. Gillies, David L. Morse, Ariosto Siqueira Silva, Arig A. Ibrahim Hashim, Robert A. Gatenby, Gary Martinez
  • Formulations of deferasirox and methods of making the same
    Patent number: 10258608
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: April 16, 2019
    Assignee: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. Miller, Justin M. Keen, Sandra U. Kucera
  • Therapeutic agent for dyslipidemia
    Patent number: 10258609
    Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: April 16, 2019
    Assignee: KOWA COMPANY, LTD.
    Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
  • Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections
    Patent number: 10258610
    Abstract: The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 16, 2019
    Assignee: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Paola Maffei, Vittoria Lauro, Fiorella Calanni, Beatrice Vitali, Federica Cruciani
  • Combination of ibudilast and riluzole and methods of using same
    Patent number: 10258611
    Abstract: The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing neurodegenerative diseases, including their progressive forms and their associated symptoms by administering a combination of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and riluzole, or pharmaceutically acceptable salts of one or both thereof.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 16, 2019
    Assignee: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Yuichi Iwaki
  • Mitochondrial lipid permeable iron chelators for treating and preventing ischemia/reperfusion (I/R) injury in the heart following an ischemic event
    Patent number: 10258612
    Abstract: Disclosed are methods and compositions for treating or preventing a disease or disorder responsive to a decrease in baseline mitochondrial iron in a subject in need thereof. The methods typically include administering a pharmaceutical composition comprising a mitochondrial permeable iron chelator to the subject.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 16, 2019
    Assignee: Northwestern University
    Inventors: Hossein Ardehali, Hsiang-Chun Chang
  • Compositions for treating retinal degeneration and methods of production and use thereof
    Patent number: 10258613
    Abstract: Compositions for use in methods of treating and/or inhibiting a pathologic ocular condition, as well as methods of producing and using same, are disclosed.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: April 16, 2019
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Xi-Qin Ding, Hongwei Ma
  • Compositions and methods for treating schizophrenia
    Patent number: 10258614
    Abstract: The disclosure provides a novel polymorph of Compound (I): 2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I).HCl.2H2O. Pharmaceutical compositions comprising Form (A) of Compound (I).HCl.2H2O and related methods of treatment are also disclosed.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: April 16, 2019
    Assignee: Minerva Neurosciences, Inc.
    Inventors: Remy Luthringer, Nadine Noel, Sandra Werner
  • Methods of treating a neurodegenerative disease in a mammal in need thereof
    Patent number: 10258615
    Abstract: The present invention provides a method of treating or ameliorating a neurodegenerative disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neurodegenerative disease drug, wherein the drug is a substrate of an ABC transporter inhibitor, wherein the mammal is further administered a therapeutically effective amount of an ABC transporter inhibitor, whereby the neurodegenerative disease is treated in the mammal. In certain embodiments, the neurodegenerative disease comprises at least one selected from the group consisting of spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, a tauopathy, and chronic traumatic encephalopathy.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: April 16, 2019
    Assignee: Thomas Jefferson University
    Inventors: Davide Trotti, Piera Pasinelli, Michael R. Jablonski
  • Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
    Patent number: 10258616
    Abstract: The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Euro-Celtique S.A.
    Inventors: Helen Kathleen Danagher, Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Jonathon Oliver Whitehouse, Thinnayam Naganathan Krishnamurthy, Ricardo Alberto Vargas Rincon
  • Dosing regimens for fast onset of antidepressant effect
    Patent number: 10258617
    Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: April 16, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Connie Sanchez Morillo, Karina Krøjer Søby, Benny Bang-Andersen
  • Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen
    Patent number: 10258618
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: April 16, 2019
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH AGING, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M. A. van Deursen
  • Combination therapy with glutaminase inhibitors and immuno-oncology agents
    Patent number: 10258619
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 16, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form
    Patent number: 10258620
    Abstract: The invention relates to the provision of a new crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium, the use of this form for medical purposes, methods for producing the crystalline form according to the invention, as well as pharmaceutical preparations comprising said form.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 16, 2019
    Assignee: Metriopharm AG
    Inventors: Thomas Martin, Josef Breu, Wolfgang Brysch, David Kosel, Beate Ludescher, Michael Niedermaier, Jörg Von Wegerer
  • Methods and compositions for treating HIV-related disorders
    Patent number: 10258621
    Abstract: Certain adjunctive therapies comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent for treating HIV-related disorders are provided herein. These disorders include AIDS dementia complex, AIDS-induced encephalopathy, HIV-associated neurocognitive disorder, asymptomatic neurocognitive impairment, minor neurocognitive disorder, minor cognitive motor disorder, vacuolar myelopathy, peripheral neuropathies, and polymyositis. Also provided are pharmaceutical compositions comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: April 16, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Leticia Toledo-Sherman